Invivoscribe Premieres 12-Color Flow Cytometry Capabilities at their Reference Labs in the US, Europe, and China
3.6.2021 23:00:00 EEST | Business Wire | Press release
Today Invivoscribe, a global leader in precision diagnostics, announced the launch of a new 12-color multiparametric flow cytometry service in Shanghai, China, the newest reference laboratory in their international LabPMM network. Flow cytometry has long been the standard of care for many blood cancers including acute myeloid leukemia (AML), but to achieve minimal residual disease (MRD) level sensitivity with limited specimen, powerful 12-color multiparametric flow cytometry (MFC) is needed. By providing the combination of 12-color flow cytometry and next-generation sequencing (NGS) MRD capabilities in the US, in Europe, and also in China, Invivoscribe now offers a comprehensive international solution for our pharma partners.
Invivoscribe’s globally standardized network of LabPMM reference laboratories offer best in class NGS assays, gene panels, and bioinformatics software, to complement our new MFC panels. The addition of 12-color MFC panels to our existing NGS capabilities, eliminates the need to split primary subject specimens and have them tested in multiple labs. It also allows the same pull of bone marrow to be tested using several complementary technologies, so pharma partners can obtain and compare results leveraging limited samples using targeted assays and technologies for drug development and clinical studies. By offering both MFC and NGS testing in our international laboratories, Invivoscribe can accelerate clinical trials and streamline drug approvals.
“We are very fortunate to have exceptional scientists leading our Flow Cytometry Services,” says Tony Lialin, Chief Commercial Officer at Invivoscribe. “Our hematopathologists are domain experts that have an intimate understanding of hematologic malignancies, the markers, and the instrumentation gained from their decades of experience. When we were developing our flow assays we had three goals: (1) to provide partners with one-stop international screening and MRD testing, (2) to leverage our infrastructure to quickly develop panels to meet novel partner needs, and (3) to provide standardized CAP/CLIA testing in all of our ISO 15189 accredited global laboratories. We are excited about our unique offering in Asia and we are well-positioned to help our pharma partners accelerate clinical studies and approval of their novel therapies worldwide.”
Leveraging an international network of our wholly-owned clinical reference laboratories, Invivoscribe can rapidly design and validate custom panels, track MRD for a range of oncologic diseases, including solid tumors, and develop and commercialize companion diagnostic assays for pharma partners.
About Invivoscribe
Invivoscribe® has been Improving Lives with Precision Diagnostics® for more than twenty-five years, advancing the field of precision medicine by developing and selling standardized reagents, tests, and bioinformatics tools to more than 700 customers in 160 countries. Invivoscribe also has a significant impact on global health working with pharmaceutical companies to accelerate approvals of new drugs and treatments by supporting international clinical trials, developing, commercializing companion diagnostics, and providing expertise in both regulatory and laboratory services. With its proven ability to provide global access to distributable reagents, kits, and controls, as well as clinical trial services through our international clinical lab subsidiaries (LabPMM®), Invivoscribe has demonstrated it is an ideal partner. For additional information please contact Invivoscribe at businessdevelopment@invivoscribe.com or visit us at www.invivoscribe.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210603005914/en/
Contact information
Tony Lialin
inquiry@invivoscribe.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TEC reduces pressure on support teams with proactive outage communications powered by Adtran and GOCare11.8.2026 15:15:00 EEST | Press release
Adtran and GOCare today announced that Telephone Electronics Corporation (TEC) has improved outage responses and reduced inbound support tickets using GOCare’s OutageIQ solution integrated with Adtran’s outage notification API and Mosaic One. Serving communities across Mississippi, Alabama and Tennessee, TEC delivers fiber broadband services built on a foundation of community investment and reliable service. By combining proactive notifications with real-time network insights, the service provider can now inform customers as issues are detected while equipping support teams with immediate context. This transparency helps build subscriber trust and streamlines operations. “Reliable connectivity is essential for the communities we serve, and clear communication during an outage makes a real difference,” said David Freytag, VP of integration at TEC. “Before this integration, service disruptions could quickly lead to high call volumes, putting pressure on our teams and leaving subscribers
Kinaxis-Sponsored Study Identifies Supply Chain AI Accountability Gap Amidst Rapid Adoption Expectations11.8.2026 15:07:00 EEST | Press release
Kinaxis® (TSX:KXS), a global leader in supply chain orchestration, today announced the findings of new independent research from IDC. The IDC InfoBrief, sponsored by Kinaxis, “Making Supply Chain AI Accountable,” reveals a growing chasm between organizations’ aggressive ambitions for autonomous AI adoption and their readiness to hold these advanced systems - which we believe underscores the need for a disciplined approach to AI investment and deployment to prevent costly failures and deliver measurable business value. What This Means for Supply Chain Leaders The IDC InfoBrief, which surveyed more than 2,000 supply chain leaders across nine global markets, found that while AI adoption is nearly universal - only 2% of respondents report no AI-enabled capabilities, and just 12% consider themselves AI leaders. Over half (52%) cite trust in AI-driven decisions as a top barrier to faster adoption, and just 12% say AI planning governance is fully embedded within their operations. The research
One in Four Executives Say AI Errors Have Reached External Audiences or Boards, According to New Research From Workiva11.8.2026 15:00:00 EEST | Press release
Workiva Inc. (NYSE: WK), a leading, audit-ready platform for trust, transparency, and accountability, today released findings from its 2026 Midyear Executive Benchmark Survey. Although 84% of surveyed executives say they are at least somewhat confident in the accuracy of AI output without human review, one in four (26%) say internal audits have detected AI errors that reached external audiences or board members. This data suggests there is a disconnect between what executives believe and what evidence shows. As AI reshapes the enterprise at unprecedented speed, a new risk is emerging: transformation could be outpacing the instincts of the leaders tasked with overseeing it. "Confidence in AI without control over data quality is a liability, not a strategy. CFOs need platforms that connect AI to trusted, auditable data so every output is one they can verify and every disclosure is one they can defend," said Barbara Larson, Chief Financial Officer at Workiva. "Getting this right is about
Altasciences Continues to Expand North American Bioanalytical Footprint11.8.2026 15:00:00 EEST | Press release
Altasciences today announced a major expansion of its North American bioanalytical laboratory footprint, reinforcing its commitment to helping sponsors accelerate drug development through increased capacity, advanced automation, and harmonized scientific operations. The expansion includes a 4,000-square-foot addition to the company’s laboratory in Greater Montréal, which is expected to be fully operational by the end of Q3 2026. The company has also announced a new 13,000-square-foot purpose-built laboratory in Harleysville, Pennsylvania. Construction will proceed in phases, with Phase 1 scheduled for completion in Q1 2027. These investments significantly increase Altasciences' ability to support the growing demand for late-stage clinical bioanalysis while providing sponsors with greater flexibility, scalability, and operational resilience. Designed to support increasingly complex development programs, the expanded laboratories will result in increased capacity to conduct larger studie
Alfasigma to Acquire Nordic Group B.V. Expanding Its Specialty Care Portfolio and Presence in Europe11.8.2026 14:30:00 EEST | Press release
Alfasigma S.p.A. (“Alfasigma”), a global pharmaceutical company, today announced that it has entered into a share purchase agreement with SEVER Life Sciences B.V. ("SEVER") for the sale of 100% of the shares of Nordic Group B.V. (“Nordic Pharma”) and its subsidiaries, a privately owned specialty pharmaceutical company with direct operations in Europe, Canada and Japan. The acquisition will add Nordic Pharma’s established rheumatoid arthritis business, led by the Nordimet® methotrexate franchise, to Alfasigma’s rheumatology portfolio, which includes the Jyseleca® franchise. It will also deepen Alfasigma’s commercial reach through direct operations in 18 countries across Europe and add commercial platforms in Canada and Japan. In addition to rheumatology, the acquisition includes Nordic Pharma’s portfolio in women’s health, critical care and ophthalmology. It also brings 265 employees with specialist capabilities and expertise. The transaction is subject to customary closing conditions,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom